Remlife Global Partners with JiyaYu Lifesciences for Sustainable Pharma Innovations

In a strategic move to redefine pharmaceutical manufacturing, Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd., has announced a transformative partnership with JiyaYu Lifesciences PTE Ltd, a company specializing in green chemistry technology. This collaboration seeks to replace animal-derived raw materials with fermentation and biocatalyst-based alternatives in the production of active pharmaceutical ingredients (APIs) and advanced intermediates.

Under the terms of the agreement, JiyaYu will license fully developed and scalable technologies exclusively to Remlife Global. These innovative solutions aim to eliminate traditional animal-based processes, instead offering sustainable, cost-effective bioprocesses that comply with regulatory standards. Remlife Global plans to scale up and commercialize these technologies at Good Manufacturing Practice (GMP) compliant sites in India, Singapore, Malta, Ireland, Belgium, and Italy, while JiyaYu has collaborated with a UK R&D platform to enhance its fermentation and biocatalyst capabilities.

The initiative is set to bolster Remlife Global's vision of reducing reliance on vulnerable supply chains by adopting cutting-edge, sustainable technologies. This project carries significant commercial potential, with projected revenues reaching Rs100 crore by FY26 and Rs200 crore by FY27, driven by innovations compatible with modern ethical and environmental standards. The partnership underscores a wider industry shift towards sustainable pharmaceutical production, ensuring safety, quality control, and environmental benefits.

(With inputs from agencies.)